Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Atria Investments Inc

Atria Investments Inc raised its position in Insmed Incorporated (NASDAQ:INSM) by 5.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,232 shares of the biopharmaceutical company’s stock after acquiring an additional 247 shares during the quarter. Atria Investments Inc’s holdings in Insmed were worth $361,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of INSM. Vestal Point Capital LP increased its stake in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the period. Victory Capital Management Inc. increased its stake in Insmed by 209.9% in the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock valued at $33,285,000 after buying an additional 308,819 shares during the period. Westfield Capital Management Co. LP acquired a new position in Insmed in the 3rd quarter valued at $18,377,000. Eventide Asset Management LLC increased its stake in Insmed by 34.2% in the 3rd quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company’s stock valued at $66,167,000 after buying an additional 231,210 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after buying an additional 214,130 shares during the period.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now directly owns 97,083 shares of the company’s stock, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the completion of the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $7,573,950.36. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock valued at $42,859,028 in the last three months. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Guggenheim reaffirmed a “buy” rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Wells Fargo & Company upped their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Insmed Stock Performance

Shares of INSM opened at $76.55 on Monday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a market cap of $13.86 billion, a price-to-earnings ratio of -13.69 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a fifty day moving average of $76.17 and a 200-day moving average of $73.69.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.